Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;16(2):207-213.
doi: 10.1038/ni.3079. Epub 2014 Dec 22.

Role and species-specific expression of colon T cell homing receptor GPR15 in colitis

Linh P Nguyen  1   2 , Junliang Pan  2 , Theresa Thanh Dinh  3 , Husein Hadeiba  2 , Edward O'Hara 3rd  2 , Ahmad Ebtikar  2 , Arnulf Hertweck  4 , M Refik Gökmen  5 , Graham M Lord  5 , Richard G Jenner  4 , Eugene C Butcher #  2   3 , Aida Habtezion #  1
Affiliations

Role and species-specific expression of colon T cell homing receptor GPR15 in colitis

Linh P Nguyen et al. Nat Immunol. 2015 Feb.

Abstract

Lymphocyte recruitment maintains intestinal immune homeostasis but also contributes to inflammation. The orphan chemoattractant receptor GPR15 mediates regulatory T cell homing and immunosuppression in the mouse colon. We show that GPR15 is also expressed by mouse TH17 and TH1 effector cells and is required for colitis in a model that depends on the trafficking of these cells to the colon. In humans GPR15 is expressed by effector cells, including pathogenic TH2 cells in ulcerative colitis, but is expressed poorly or not at all by colon regulatory T (Treg) cells. The TH2 transcriptional activator GATA-3 and the Treg-associated transcriptional repressor FOXP3 robustly bind human, but not mouse, GPR15 enhancer sequences, correlating with receptor expression. Our results highlight species differences in GPR15 regulation and suggest it as a potential therapeutic target for colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
GPR15 mediates accumulation of TEM and Treg cells in the colon. (a) Gpr15–KO (CD45.2) or het (CD45.2) bone marrow cells were combined with Gpr15-het (CD45.1) cells and transferred into irradiated hosts (CD45.1 × CD45.2 F1) to generate experimental (Exp) or control (Ctrl) chimeras, respectively, as in Supplementary Figure 2a. Ratios of Gpr15–KO to Gpr15–het derived cells (CD45.2/CD45.1) among Treg cells (CD4+, CD25hi, Foxp3+; top), Treg–excluded TEM cells (CD4+, Foxp3−, CD44hi, CD45RBlo; middle), and naive CD4+ T cells (CD4+, Foxp3−, CD44lo, CD45RBhi; bottom) in Exp mixed bone marrow chimeras (white bars); ratios of Gpr15- het to het cells (CD45.2/CD45.1) in control chimeras (black bars). Peripheral lymph nodes (PLN), mesenteric lymph node (MLN), Peyer’s patches (PP), small intestine (SI). n = 3, mean + SEM, **p <0.01 (2–way ANOVA, Bonferonni posttest). Representative of 3 experiments. (b) Splenocytes from DO11.10 Gpr15–het or DO11.10 Gpr15–KO were i.v. injected into Balb/c (Thy–1.1) mice. After 24 h, recipients were treated intra-rectally with ovalbumin (OVA) and cholera toxin (CT). Accumulation of OVA-specific CD4+ T cells in tissues was assessed 5 days later, as in Supplementary Figure 2c. The percent antigen–specific (DO11+) of Gpr15-het or KO CD4+ TEM cells (CD44hi, CD45RBlo) 5 days after antigen exposure was normalized to the ratio in the spleen. Data from 9 mice from 3 independent experiments are shown. Mean ± SEM, *p <0.05 (2–way ANOVA, Bonferroni posttest). (c) Similar proliferation rate of antigen–reactive Gpr15–het and Gpr15–KO cells. CFSE–labeled splenocytes from Gpr15–het (Thy–1.1, Thy–1.2) and KO (Thy–1.2) DO11 mice were co–injected i.v. in equal proportion into congenic non–DO11 hosts (Thy–1.1) on day 0. Recipients were treated with OVA and CT per rectum on day 1, FTY720 or PBS i.p on day 3, and tissues were collected on day 5, as in Supplementary Figure 2e. (d) Recipient MLN gated on donor DO11+ CD4+ T cells. n = 3; mean + SEM. Not significant (NS).
Figure 2
Figure 2
GPR15–deficient naive T cells fail to induce colitis in the CD45RBhi CD4+ T cell transfer model. (a) Weight loss of Rag2−/− mice that received either WT naive CD4+ T cells, Gpr15–KO naive CD4+ T cells, WT naive plus WT Treg cells, WT naive plus KO Treg cells, or KO naive plus WT Treg cells. n = 5, mean + SEM, *p <0.05, **p <0.01 between WT naive (disease control) and Gpr15 KO naive (2-way ANOVA, Bonferroni posttest). Representative of 3 experiments. (b) Clinical score for histological inflammation in colon. *p <0.05, **p < 0.01, ***p <0.001 (1–way ANOVA, Tukey’s posttest). (c) H&E staining of distal colon section: WT naive (top left), Gpr15–KO naive (top right), WT naive + WT Treg (middle left), WT naive + Gpr15–KO Treg (middle right) and Gpr15–KO naive and WT Treg (bottom). Scale bar denotes 10 μm.
Figure 3
Figure 3
GPR15 deficiency inhibits effector T cell accumulation in the colon, but not TH1 or TH17 differentiation. Naive CD45RBhi CD4+ T cells sorted from Gpr15–KO (CD45.2) or het (CD45.1, CD45.2) mice were co–injected into Rag2−/− recipients in equal proportion, as in Supplementary Figure 5a. (a) Ratios Gpr15–het to Gpr15–KO GFP+ or GFP− CD4+ T cells in recipient tissues after 2 weeks, normalized to those in the spleen. n = 5, mean + SEM, *p <0.001. (2–way ANOVA, Bonferroni posttest). (b) Similar percentage of Gpr15–het- and KO-derived IFN-γ and IL–17+ CD4+ T cells in recipient colon after 2 weeks (left). Ratio of Gpr15– het- to KO-derived IFN–γ+ or IL–17+ CD4+ T cells, normalized to that of the spleen (right). Representative of 2 experiments. (c) BrdU incorporation 2 weeks after cell transfer as in (a); baseline (grey shade). n = 3; mean + SEM.
Figure 4
Figure 4
Human proinflammatory CD4+ T cells express GPR15 in the colon. (a) Expression of GPR15 on cytokine–producing CD45RO+CD4+ T cells from ulcerative colitis (UC) or non–UC colons (top). In UC colons, GPR15 is expressed on IL–5+ and IL–13+ CD45RO+CD4+ T cells (bottom). n = 5 UC specimens, 11 Non–UC or normal samples, and 2 Crohn’s disease (CD) colons, which showed similar cytokine expression among GPR15+ cells as normal samples. Mean + SEM; *p <0.05, **p < 0.01, ***p <0.001 (2–way ANOVA, Bonferroni posttest). Statistics not determined for CD samples. (b) Lower expression of GPR15 on Treg cells (CD127lo, Foxp3+; red histogram) as compared to non–T memory CD4+ Treg, cells (CD127hi, Foxp3−; blue).
Figure 5
Figure 5
Distinct patterns of GPR15 expression by in vitro–polarized human and mouse T cells. Naive CD4+ T cells enriched from human PBMC (a) or mouse Gpr15–het spleen (b) were polarized as described in the online methods. GPR15 is expressed on human but not mouse in vitro–polarized TH2 cells. Human cells are gated on CD45RO+ CD4+ T cells, and mouse cells are gated on CD44hi CD4+ T cells. Combined results of 3 mouse and 4 human experiments; mean + SEM.
Figure 6
Figure 6
Differential binding of GATA–3 to human and mouse Gpr15 enhancer sequences. (a) ChIP–Seq data showing binding of GATA–3 at the human GPR15 locus in TH2 cells. The number of sequencing reads from ChIP–enriched DNA are plotted per million background–subtracted total reads and aligned with the Hg18 build of the human genome. Association with H3K4me3 and H3K27ac in human TH1 and TH2 cells are shown below. The position of the upstream enhancer is marked with a dashed box. The positions of qPCR primers used in (c) are marked by arrows. (b) As (a), except for Gata–3 and H3K4me3 at the mouse Gpr15 locus (Mm9 build). (c) Enrichment of DNA corresponding to the human and mouse upstream and downstream GATA–3 binding sites marked in (a) and (b), relative to input DNA and a control non–bound region (also marked in (a) and (b)), measured by ChIP–qPCR. Mean and SD from triplicate wells from one ChIP per species. *p < 0.05, unpaired Student’s t–test.
See this image and copyright information in PMC

Comment in

  • GPR15: a tale of two species.
    Bilsborough J, Viney JL. Bilsborough J, et al. Nat Immunol. 2015 Feb;16(2):137-9. doi: 10.1038/ni.3084. Nat Immunol. 2015. PMID: 25594457 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Islam SA, Luster AD. T cell homing to epithelial barriers in allergic disease. Nat Med. 2012;18:705–715. doi:10.1038/nm.2760. - PMC - PubMed
    1. Mora JR, Von Andrian UH. Specificity and plasticity of memory lymphocyte migration. Curr Top Microbiol Immunol. 2006;308:83–116. - PubMed
    1. Zabel BA, Rott A, Butcher EC. Leukocyte Chemoattractant Receptors in Human Disease Pathogenesis. Annual review of pathology. 2014 doi:10.1146/annurev-pathol-012513-104640. - PubMed
    1. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol. 2002;283:R7–28. doi:10.1152/ajpregu.00738.2001. - PubMed
    1. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16:1–4. - PubMed

Publication types

MeSH terms